These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7952656)

  • 1. Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors.
    Rosé JR; Craik CS
    Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 2):S176-82. PubMed ID: 7952656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design.
    Rutenber E; Fauman EB; Keenan RJ; Fong S; Furth PS; Ortiz de Montellano PR; Meng E; Kuntz ID; DeCamp DL; Salto R
    J Biol Chem; 1993 Jul; 268(21):15343-6. PubMed ID: 8340363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization of nonpeptide irreversible inhibitors of HIV proteases.
    Salto R; Babé LM; Li J; Rosé JR; Yu Z; Burlingame A; De Voss JJ; Sui Z; Ortiz de Montellano P; Craik CS
    J Biol Chem; 1994 Apr; 269(14):10691-8. PubMed ID: 8144659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.
    DesJarlais RL; Seibel GL; Kuntz ID; Furth PS; Alvarez JC; Ortiz de Montellano PR; DeCamp DL; Babé LM; Craik CS
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6644-8. PubMed ID: 2204060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
    J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S; Ross P; Freire E
    Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
    Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
    J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
    Cihlar T; He GX; Liu X; Chen JM; Hatada M; Swaminathan S; McDermott MJ; Yang ZY; Mulato AS; Chen X; Leavitt SA; Stray KM; Lee WA
    J Mol Biol; 2006 Oct; 363(3):635-47. PubMed ID: 16979654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
    Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
    Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.
    Bouzide A; Sauvé G; Yelle J
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1509-13. PubMed ID: 15713418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK
    J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.
    Schimer J; Cígler P; Veselý J; Grantz Šašková K; Lepšík M; Brynda J; Rezáčová P; Kožíšek M; Císařová I; Oberwinkler H; Kraeusslich HG; Konvalinka J
    J Med Chem; 2012 Nov; 55(22):10130-5. PubMed ID: 23050738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H; Freire E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
    Dunn BM; Pennington MW; Frase DC; Nash K
    Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying the molecular mechanics and binding dynamics characteristics of potent inhibitors to HIV-1 protease.
    Li D; Liu MS; Ji B; Hwang KC; Huang Y
    Chem Biol Drug Des; 2012 Sep; 80(3):440-54. PubMed ID: 22621379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.